English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The aim of the study was to evaluate the clinical efficacy and cardioprotective effects of olmesartan and lercanidipine in the form of monotherapy and combined use in patients with arterial hypertension (AH) 1-2 degree and the presence of target organ damage in the form of left ventricular hypertrophy (LVH) and microalbuminuria UIA). Materials and methods. 90 patients with AH of 1-2 degree were examined and presence of LVH according to echocardiography (EchoCG) data, middle age 50.3±4.3 years, 42 of them men and 48 women, with AH of 1st degree - 44 (48.9%) people, with AH of the 2nd degree - 46 (51.1%) people. The mean duration of hypertension was 6.8±1.5 years. Methods included daily monitoring of blood pressure (cardiovascular system): CardioTens (Meditech, Hungary), transthoracic EchoCG: Voluson 730 Expert (General Electric, USA). One of the inclusion criteria was the presence of LVH according to EchoCG data: more than 95 g/m2 in women and more than 115 g/m2 in men. Depending on the initial degree of hypertension patients were divided into 3 groups. Patients with the 1st degree of AH were randomized to olmesartan monotherapy with 10-40 mg/day (group 1) and lercanidipine 10-20 mg/day (group 2), with grade 2 AH included in the combination therapy group Studied drugs (3rd group). Doses of drugs were titrated until the target blood pressure levels were reached. Initially and after 6 months of therapy, the results of SMAD, EchoCG were evaluated, the quality of life of patients was assessed using the visual-analogue scale "Health thermometer". The statistical analysis was carried out using the program Statistica 7.0. Results of the study. The degree of significant decrease in blood pressure in comparison with the baseline values and the corrective effect on the daily profile of blood pressure were comparable in the monotherapy groups with olmesartan and lercanidipine. In the group of combined use of target drugs of target levels, blood pressure was achieved in a larger percentage of cases than in the monotherapy groups. A reliable cardioprotective effect of olmesartan and lercanidipine was revealed both in monotherapy and in combination in patients with AH of 1-2 degree with LVH and MAU, manifested by a decrease in LV mass index (LVMI). The greatest cardioprotective effect in LVH regression was achieved in the combination therapy group. Conclusion. Olmesartan and lercanidipine when used in monotherapy have a cardioprotective effect in the form of a reliable and comparable decrease in LVMI, and their use in combination has a more pronounced effect on LVH regression.

cardiosomatika

Clinical efficacy and cardioprotective capabilities of olmesartan and lercanidipine in the form of monotherapy and with their combined use in patients with arterial hypertension 1-2 degree